GlassScriptPhysician profile
Derene E Akins
NPI 1164530911
$465.10
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $13.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $162.13 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.63 | 2019-2020 | |
| Amarin Pharma, INC. | $44.51 | 2019 | |
| Glaxosmithkline, LLC. | $32.17 | 2019 | |
| Celgene Corporation | $26.26 | 2019 | |
| Daiichi Sankyo INC. | $19.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.37 | 2019 | |
| Novo Nordisk INC | $13.10 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.56 | 2019 | |
| Amgen INC. | $12.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derene Akins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.